Tags

Type your tag names separated by a space and hit enter

Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial.
Eur J Contracept Reprod Health Care. 2016 Jun; 21(3):220-6.EJ

Abstract

OBJECTIVES

The aim of our study was to compare acceptability of the copper intrauterine device (Cu-IUD) and levonorgestrel-releasing intrauterine system (LNG-IUS) among women living with the human immunodeficiency virus (HIV).

METHODS

We randomly assigned 703 HIV-positive women in Uganda to receive either a Cu-IUD or an LNG-IUS and followed them for at least one year. During the follow-up visits, face-to-face interviews were conducted with the women and acceptability of the Cu-IUD or LNG-IUS was assessed, using a Likert scale, at one, three, six and twelve months. At the final follow-up visit, women were also assessed for satisfaction with either method.

RESULTS

Between 9 September 2013 and 31 December 2014, 703 women were recruited and assigned as follows: 349 to a Cu-IUD group and 354 to an LNG-IUS group. Acceptability decreased from 94.3% at one month to 87.7% at 12 months in the Cu-IUD group and from 96.3% at one month to 86.7% at 12 months in the LNG-IUS group (p = 0.97). Satisfaction with intrauterine contraception was reported by 83.7% (283/338) in the Cu-IUD group and by 90.4% (302/334) in the LNG-IUS group (p = 0.50).

CONCLUSIONS

There was no significant difference in acceptability between the LNG-IUS and Cu-IUD among HIV-positive women. Satisfaction rates were high and similar in the two groups. Both the Cu-IUD and LNG-IUS are acceptable forms of contraception for HIV-positive women and should be made available to women in HIV care to increase their contraceptive method options.

CLINICAL TRIAL REGISTRATION

The trial is registered at the Pan African Clinical Trials Registry (PACTR 201308000561212).

Authors+Show Affiliations

a Department of Obstetrics and Gynaecology School of Medicine , Makerere University College of Health Sciences, Mulago National Referral Hospital, Kampala, Uganda ;b Department of Biostatistics and Epidemiology, School of Public Health , Makerere University College of Health Sciences, Mulago National Referral Hospital , Kampala , Uganda ;a Department of Obstetrics and Gynaecology School of Medicine , Makerere University College of Health Sciences, Mulago National Referral Hospital, Kampala, Uganda ;c Division of Obstetrics and Gynaecology, Department of Women's and Children's Health , Karolinska Institutet, WHO Centre C1:05, Karolinska University Hospital , Stockholm , Sweden.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

26895345

Citation

Kakaire, Othman, et al. "Acceptability of Intrauterine Contraception Among Women Living With Human Immunodeficiency Virus: a Randomised Clinical Trial." The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception, vol. 21, no. 3, 2016, pp. 220-6.
Kakaire O, Tumwesigye NM, Byamugisha JK, et al. Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial. Eur J Contracept Reprod Health Care. 2016;21(3):220-6.
Kakaire, O., Tumwesigye, N. M., Byamugisha, J. K., & Gemzell-Danielsson, K. (2016). Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial. The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception, 21(3), 220-6. https://doi.org/10.3109/13625187.2016.1146249
Kakaire O, et al. Acceptability of Intrauterine Contraception Among Women Living With Human Immunodeficiency Virus: a Randomised Clinical Trial. Eur J Contracept Reprod Health Care. 2016;21(3):220-6. PubMed PMID: 26895345.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial. AU - Kakaire,Othman, AU - Tumwesigye,Nazarius Mbona, AU - Byamugisha,Josaphat Kayogoza, AU - Gemzell-Danielsson,Kristina, Y1 - 2016/02/19/ PY - 2016/2/20/entrez PY - 2016/2/20/pubmed PY - 2017/4/30/medline KW - Copper IUD KW - HIV-positive women KW - IUC acceptability KW - LNG-IUS KW - intrauterine contraception SP - 220 EP - 6 JF - The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception JO - Eur J Contracept Reprod Health Care VL - 21 IS - 3 N2 - OBJECTIVES: The aim of our study was to compare acceptability of the copper intrauterine device (Cu-IUD) and levonorgestrel-releasing intrauterine system (LNG-IUS) among women living with the human immunodeficiency virus (HIV). METHODS: We randomly assigned 703 HIV-positive women in Uganda to receive either a Cu-IUD or an LNG-IUS and followed them for at least one year. During the follow-up visits, face-to-face interviews were conducted with the women and acceptability of the Cu-IUD or LNG-IUS was assessed, using a Likert scale, at one, three, six and twelve months. At the final follow-up visit, women were also assessed for satisfaction with either method. RESULTS: Between 9 September 2013 and 31 December 2014, 703 women were recruited and assigned as follows: 349 to a Cu-IUD group and 354 to an LNG-IUS group. Acceptability decreased from 94.3% at one month to 87.7% at 12 months in the Cu-IUD group and from 96.3% at one month to 86.7% at 12 months in the LNG-IUS group (p = 0.97). Satisfaction with intrauterine contraception was reported by 83.7% (283/338) in the Cu-IUD group and by 90.4% (302/334) in the LNG-IUS group (p = 0.50). CONCLUSIONS: There was no significant difference in acceptability between the LNG-IUS and Cu-IUD among HIV-positive women. Satisfaction rates were high and similar in the two groups. Both the Cu-IUD and LNG-IUS are acceptable forms of contraception for HIV-positive women and should be made available to women in HIV care to increase their contraceptive method options. CLINICAL TRIAL REGISTRATION: The trial is registered at the Pan African Clinical Trials Registry (PACTR 201308000561212). SN - 1473-0782 UR - https://www.unboundmedicine.com/medline/citation/26895345/Acceptability_of_intrauterine_contraception_among_women_living_with_human_immunodeficiency_virus:_a_randomised_clinical_trial_ L2 - https://www.tandfonline.com/doi/full/10.3109/13625187.2016.1146249 DB - PRIME DP - Unbound Medicine ER -